GlassScriptPhysician profile
Jose R Soler
NPI 1639163207
$9,177.01
in general payments reported to CMS, 2019-2025
22 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,889 · 2020: $1,164 · 2021: $2,044 · 2022: $940 · 2023: $1,032 · 2024: $647 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,769 · Travel and Lodging: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.42 |
| Travel and Lodging | $369.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,905.25 | 2019-2023 | Aveir |
| Boston Scientific Corporation | $1,126.32 | 2019-2025 | Watchman Access System, General - Therapies |
| Janssen Pharmaceuticals, INC | $1,038.68 | 2019-2022 | |
| Heartflow, INC. | $745.20 | 2022-2025 | Ffrct |
| Amgen INC. | $715.32 | 2019-2022 | |
| Medtronic, INC. | $576.69 | 2021-2025 | Cobalt Dr Mri Surescan, Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.75 | 2019-2023 | Jardiance |
| Pfizer INC. | $413.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $401.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $348.86 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $307.76 | 2019-2023 | |
| Amarin Pharma, INC. | $280.51 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $198.73 | 2019-2022 | |
| Medtronic Vascular, INC. | $158.50 | 2019-2020 | |
| Astellas Pharma US INC | $116.93 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.15 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $72.18 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $58.70 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $46.70 | 2019 | |
| Xeris Pharmaceuticals, INC. | $38.36 | 2021 | |
| Ethicon US, LLC | $19.52 | 2020 | |
| Preventice Services, LLC | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Soler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.